Investigational drug · Phase 3
NSC 613327
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer, Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
13
Any phase or sponsor naming "NSC 613327"
First trial start
2023
Apr 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NSC 613327", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced Triple-negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Advanced Triple-Negative Breast Cancer
Approved drugs for the same conditions: Breast cancer · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "NSC 613327" as an intervention, largest first.
- A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast CancerPivotal-lookingRecruiting
BeBetter Med IncIndustry
NCT07544056 · 446 participants (planned) · Start Jun 4, 2026 · Primary completion Jun 2030
Drug: BEBT-209 capsules; Carboplatin Injection and 1 more · For: Locally Advanced Triple-negative Breast Cancer; Metastatic Triple-negative Breast Cancer
Sites: Guangzhou, China; Changsha, China
- Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaPivotal-lookingRecruiting
BeBetter Med IncIndustry
NCT06792253 · 416 participants (planned) · Start Jan 6, 2025 · Primary completion Dec 31, 2028
Drug: Ifupinostat Hydrochloride for Injection; Rituximab Injection and 5 more · For: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sites: Beijing, China
- Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine LeiomyosarcomaPivotal-lookingTerminated
National Cancer Institute (NCI)NIH
NCT01012297 · 107 participants · Start Nov 2009 · Primary completion Sep 2015
Drug: Bevacizumab; Docetaxel and 3 more · For: Recurrent Uterine Corpus Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma and 4 more
Sites: Phoenix, Arizona; Burbank, California; Concord, California · 201 sites in all
- Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaStatus unknown
BeBetter Med IncIndustry
NCT06164327 · 75 participants (planned) · Start Dec 1, 2023 · Primary completion Oct 31, 2025
Drug: BEBT-908 for Injection; Rituximab Injection and 5 more · For: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sites: Beijing, China
BeBetter Med IncIndustry
NCT06685796 · 65 participants · Start Apr 12, 2023 · Primary completion Apr 20, 2026
Drug: BEBT-209 capsules; Carboplatin injection and 1 more · For: Advanced Triple-Negative Breast Cancer
Sites: Guangzhou, China; Changsha, China
Gynecologic Oncology GroupResearch network
NCT01595061 · 57 participants · Start Jul 2, 2012 · Primary completion Sep 23, 2020
Drug: Cisplatin; Gemcitabine Hydrochloride · For: Stage III Vulvar Cancer AJCC v7; Stage IIIA Vulvar Cancer AJCC v7; Stage IIIB Vulvar Cancer AJCC v7 and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Burbank, California · 193 sites in all
- Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by SurgeryPivotal-lookingTerminated
Gynecologic Oncology GroupResearch network
NCT01533207 · 38 participants · Start Jun 4, 2012 · Primary completion Jun 30, 2018
Drug: Docetaxel; Doxorubicin Hydrochloride and 3 more · For: Stage I Uterine Sarcoma AJCC v7; Uterine Corpus Leiomyosarcoma
Sites: Huntsville, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 623 sites in all
Children's Oncology GroupResearch network
NCT00070304 · 33 participants · Start Jul 2004 · Primary completion Sep 2007
Drug: filgrastim; gemcitabine hydrochloride and 1 more · For: Lymphoma
Sites: Birmingham, Alabama; Little Rock, Arkansas; Downey, California · 123 sites in all
Children's Oncology GroupResearch network
NCT00006462 · 32 participants · Start Apr 2001 · Primary completion Aug 2003
Drug: gemcitabine hydrochloride · For: Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 225 sites in all
National Cancer Institute (NCI)NIH
NCT00005577 · 30 participants · Start Aug 1996 · Primary completion Sep 2002
Drug: gemcitabine hydrochloride · For: Unspecified Childhood Solid Tumor, Protocol Specific
Sites: Los Angeles, California; Orange, California; San Francisco, California · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Locally Advanced Triple-negative Breast Cancer
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- BEBT-209KCBI-0191Phase 33 trials
BeBetter Med Inc · HR+/HER2- Locally Advanced, Metastatic Breast Cancer, Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.